1200130-82-0

Basic information

• Product Name: 6-broMo-5-iodonicotinic acid
• Synonyms: 6-broMo-5-iodonicotinic acid
• CAS NO: 1200130-82-0
• Molecular Formula: C6H3BrINO2
• Molecular Weight: 327.90199
• Mol File: 1200130-82-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-broMo-5-iodonicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-broMo-5-iodonicotinic acid(1200130-82-0)
• EPA Substance Registry System: 6-broMo-5-iodonicotinic acid(1200130-82-0)

Safety Data

• Hazardous Substances Data: 1200130-82-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-5-iodonicotinic acid is used as a synthetic reagent for the production of antitumor naphthyridines. These naphthyridines are a class of compounds with significant potential in the development of anticancer drugs, as they can inhibit the activity of certain enzymes and disrupt essential cellular processes in cancer cells, thereby exhibiting antitumor properties.
In the synthesis of antitumor naphthyridines, 6-bromo-5-iodonicotinic acid serves as a key building block, providing the necessary structural features that can be further modified and functionalized to create a diverse range of naphthyridine-based anticancer agents. The presence of the bromine and iodine atoms in the molecule allows for various chemical reactions, such as substitution, addition, and cross-coupling, which can be exploited to construct the desired naphthyridine scaffolds with specific biological activities.
Furthermore, the use of 6-bromo-5-iodonicotinic acid in the pharmaceutical industry highlights its importance in the development of novel therapeutic agents for the treatment of cancer. As research continues to explore the potential of naphthyridines and other related compounds, 6-bromo-5-iodonicotinic acid is expected to play a crucial role in the discovery and synthesis of new and effective antitumor drugs.

Upstream product

• 6311-35-9 6-bromonicotinic acid 

Downstream Products

• 1200130-47-7 3-(4-(piperidin-1-ylmethyl)phenyl)-6-(pyrimidin-5-yl)-9H-pyrrolo-[2,3-b:5,4-c′]dipyridine 
• 1200130-45-5 3-(4-(piperidin-1-ylmethyl)phenyl)-6-(pyrazin-2-yl)-9H-pyrrolo-[2,3-b:5,4-c′]dipyridine 
• 1200130-39-7 3-(4-(piperidin-1-ylmethyl)phenyl)-6-(pyridin-4-yl)-9H-pyrrolo-[2,3-b:5,4-c′]dipyridine 
• 1200130-38-6 3-(4-(piperidin-1-ylmethyl)phenyl)-6-(pyridin-3-yl)-9H-pyrrolo-[2,3-b:5,4-c′]dipyridine 
• 1200129-78-7 6-(1-methyl-1H-pyrazol-4-yl)-3-(4-(piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c′]dipyridine 
• 1200130-28-4 4-(3-(4-(piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c′]-dipyridin-6-yl)isoxazole 
• 1200129-84-5 5-(3-(4-(piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c′]-dipyridin-6-yl)thiazole 
• 1200130-25-1 5-(3-(4-(piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c′]-dipyridin-6-yl)oxazole 
• 1200129-85-6 3-(4-(piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c′]-dipyridine 
• 1200130-00-2 6-bromo-3-(4-(piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c′]dipyridine 

Relevant articles and documents

NAPHTHYRIDINE COMPOUNDS AND USES THEREOF

Naphthyridine compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1- dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1

Checkpoint kinase 1 (ChK1) plays a key role in the DNA damage response, facilitating cell-cycle arrest to provide sufficient time for lesion repair. This leads to the hypothesis that inhibition of ChK1 might enhance the effectiveness of DNA-damaging therapies in the treatment of cancer. Lead compound 1 (GNE-783), the prototype of the 1,7-diazacarbazole class of ChK1 inhibitors, was found to be a highly potent inhibitor of acetylcholine esterase (AChE) and unsuitable for development. A campaign of analogue synthesis established SAR delineating ChK1 and AChE activities and allowing identification of new leads with improved profiles. In silico docking using a model of AChE permitted rationalization of the observed SAR. Compounds 19 (GNE-900) and 30 (GNE-145) were identified as selective, orally bioavailable ChK1 inhibitors offering excellent in vitro potency with significantly reduced AChE activity. In combination with gemcitabine, these compounds demonstrate an in vivo pharmacodynamic effect and are efficacious in a mouse p53 mutant xenograft model.

DIAZACARBAZOLES AND METHODS OF USE

The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chkl) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.